Trial
NCT06356259
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
ImmunoRx Pharma Inc.
Collaborators
—
Condition
Healthy Participants
Intervention
IRX-010
Why stopped
The highest multiple dose planned for this study was not well tolerated by most participants. There is no benefit to continue dosing of healthy participants.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-26